CUBT
Curative Biotechnology, Inc.
Price Chart
Latest Quote
$1.30
-0.15 (-10.34%)
Current Price
| Previous Close | $1.45 |
| Open | $1.30 |
| Day High | $1.30 |
| Day Low | $1.30 |
| Volume | 100 |
Stock Information
| Shares Outstanding | 7.66M |
| Total Debt | $3.48M |
| Cash Equivalents | $31K |
| Net Income | $-2.84M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $9.96M |
| EPS (TTM) | $-1.02 |
| Exchange | OID |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $13.82M |
| Income | $-2.84M |
| Book/sh | $-0.82 |
| Cash/sh | $0.00 |
Financial Ratios
| Quick Ratio | 0.00 |
| Current Ratio | 0.01 |
Returns & Margins
Ownership
| Insider Ownership | 0.04% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -1.58 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.52 |
| SMA50 | $1.30 |
| SMA200 | $1.15 |
| RSI | 44.46 |
| ATR | 0.1140 |
| Shares Float | 5.73M |
| Volatility | 1.39 |
| Rel Volume | 0.33 |
Performance History
| Week | -15.03% |
| Month | -20.25% |
| Quarter | +15.56% |
| 6 Months | +9.01% |
| YTD | +75.08% |
| Year | +9.70% |
| 3 Years | -70.22% |
| 5 Years | -90.04% |
| 10 Years | +4233.48% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $1.30 | 144 |
| 2026-06-16 | $1.45 | 529 |
| 2026-06-15 | $1.54 | 200 |
| 2026-06-12 | $1.40 | 376 |
| 2026-06-11 | $1.54 | 820 |
| 2026-06-10 | $1.53 | 200 |
| 2026-06-09 | $1.54 | 943 |
| 2026-06-08 | $1.55 | 167 |
| 2026-06-05 | $1.58 | 308 |
| 2026-06-04 | $1.55 | 100 |
| 2026-06-03 | $1.70 | 2,216 |
| 2026-06-02 | $1.61 | 301 |
| 2026-06-01 | $1.61 | 283 |
| 2026-05-29 | $1.61 | 207 |
| 2026-05-28 | $1.41 | 121 |
| 2026-05-27 | $1.36 | 113 |
| 2026-05-26 | $1.50 | 110 |
| 2026-05-22 | $1.50 | 1,034 |
| 2026-05-21 | $1.44 | 133 |
| 2026-05-20 | $1.61 | 484 |
| 2026-05-19 | $1.60 | 10,892 |
| 2026-05-18 | $1.63 | 100 |
About Curative Biotechnology, Inc.
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine; and development agreement with the University of Pennsylvania School of Veterinary Medicine for the development of a metformin-based ophthalmic formulation. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.
Period:
Loading...
Income Statement (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Revenue | ||
| Reconciled Cost Of Revenue | $0 | $0 |
| Cost Of Revenue | $0 | $0 |
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Interest Expense | $1,170,319 | $176,672 |
| Total Expenses | $4,435,688 | $4,997,374 |
| Other Income Expense | $1,114 | $-166,308 |
| Other Non Operating Income Expenses | $4,914 | - |
| Net Non Operating Interest Income Expense | $-1,170,319 | $-176,672 |
| Interest Expense Non Operating | $1,170,319 | $176,672 |
| Operating Expense | $4,435,688 | $4,997,374 |
| General And Administrative Expense | $1,945,653 | $4,211,355 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-5,604,893 | $-5,340,354 |
| Net Interest Income | $-1,170,319 | $-176,672 |
| Normalized Income | $-5,601,093 | $-5,174,046 |
| Net Income From Continuing And Discontinued Operation | $-5,604,893 | $-5,340,354 |
| Total Operating Income As Reported | $-4,439,488 | $-5,014,332 |
| Net Income Common Stockholders | $-5,604,893 | $-5,340,354 |
| Net Income | $-5,604,893 | $-5,340,354 |
| Net Income Including Noncontrolling Interests | $-5,604,893 | $-5,340,354 |
| Net Income Continuous Operations | $-5,604,893 | $-5,340,354 |
| Pretax Income | $-5,604,893 | $-5,340,354 |
| Special Income Charges | $-3,800 | $-166,308 |
| Operating Income | $-4,435,688 | $-4,997,374 |
| Depreciation Amortization Depletion Income Statement | $7,956 | $6,744 |
| Depreciation And Amortization In Income Statement | $7,956 | $6,744 |
| Gross Profit | $0 | $0 |
| Per Share | ||
| Diluted EPS | $-0.01 | $-0.01 |
| Basic EPS | $-0.01 | $-0.01 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,422,818 | $-4,990,630 |
| Total Unusual Items | $-3,800 | $-166,308 |
| Total Unusual Items Excluding Goodwill | $-3,800 | $-166,308 |
| Reconciled Depreciation | $7,956 | $6,744 |
| EBITDA (Bullshit earnings) | $-4,426,618 | $-5,156,938 |
| EBIT | $-4,434,574 | $-5,163,682 |
| Diluted Average Shares | $572,009,911 | $3,402,157 |
| Basic Average Shares | $572,009,911 | $3,402,157 |
| Diluted NI Availto Com Stockholders | $-5,604,893 | $-5,340,354 |
| Impairment Of Capital Assets | $3,800 | $16,958 |
| Research And Development | $2,482,079 | $779,275 |
| Selling General And Administration | $1,945,653 | $4,211,355 |
| Other Gand A | $1,945,653 | $4,211,355 |
| Other Special Charges | - | $149,350 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-22,153,892 | $-17,920,292 |
| Total Assets | $2,089,191 | $2,412,150 |
| Total Non Current Assets | $2,020,523 | $1,658,245 |
| Non Current Deferred Assets | $390,104 | $92,975 |
| Goodwill And Other Intangible Assets | $1,624,155 | $1,558,550 |
| Current Assets | $68,668 | $753,905 |
| Prepaid Assets | $10,000 | $58,642 |
| Receivables | $0 | $25,000 |
| Cash Cash Equivalents And Short Term Investments | $58,668 | $670,263 |
| Cash And Cash Equivalents | $58,668 | $670,263 |
| Cash Financial | $58,668 | $670,263 |
| Other Receivables | - | $25,000 |
| Debt | ||
| Net Debt | $1,011,980 | - |
| Total Debt | $1,070,648 | - |
| Current Debt And Capital Lease Obligation | $1,070,648 | - |
| Current Debt | $1,070,648 | - |
| Other Current Borrowings | $870,648 | - |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $22,618,928 | $18,773,892 |
| Total Non Current Liabilities Net Minority Interest | $18,131,825 | $18,043,557 |
| Current Liabilities | $4,487,103 | $730,335 |
| Other Current Liabilities | $21,911 | $3,431 |
| Current Notes Payable | $200,000 | $0 |
| Payables And Accrued Expenses | $3,394,544 | $726,904 |
| Equity | ||
| Common Stock Equity | $-20,529,757 | $-16,361,750 |
| Preferred Stock Equity | $20 | $8 |
| Total Equity Gross Minority Interest | $-20,529,737 | $-16,361,742 |
| Stockholders Equity | $-20,529,737 | $-16,361,742 |
| Retained Earnings | $-32,610,198 | $-26,917,036 |
| Preferred Securities Outside Stock Equity | $18,131,825 | $18,043,557 |
| Other | ||
| Ordinary Shares Number | $579,271,135 | $537,881,194 |
| Share Issued | $579,271,135 | $537,881,194 |
| Tangible Book Value | $-22,153,912 | $-17,920,300 |
| Invested Capital | $-19,459,109 | $-16,361,750 |
| Working Capital | $-4,418,435 | $23,570 |
| Total Capitalization | $-20,529,737 | $-16,361,742 |
| Additional Paid In Capital | $12,022,514 | $10,498,221 |
| Capital Stock | $57,947 | $57,073 |
| Common Stock | $57,927 | $57,065 |
| Preferred Stock | $20 | $8 |
| Net PPE | $6,264 | $6,720 |
| Accumulated Depreciation | $-570 | $-114 |
| Gross PPE | $6,834 | $6,834 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-1,612,478 | $-1,625,369 |
| Operating Activities | ||
| Operating Cash Flow | $-1,535,573 | $-1,604,035 |
| Cash Flow From Continuing Operating Activities | $-1,535,573 | $-1,604,035 |
| Operating Gains Losses | - | $149,350 |
| Investing Activities | ||
| Capital Expenditure | $-76,905 | $-21,334 |
| Investing Cash Flow | $-76,905 | $-21,334 |
| Cash Flow From Continuing Investing Activities | $-76,905 | $-21,334 |
| Financing Activities | ||
| Issuance Of Capital Stock | $116,000 | $1,573,000 |
| Financing Cash Flow | $1,000,883 | $2,065,025 |
| Cash Flow From Continuing Financing Activities | $1,000,883 | $2,065,025 |
| Net Other Financing Charges | $-250,779 | $-92,975 |
| Net Preferred Stock Issuance | $116,000 | $0 |
| Preferred Stock Issuance | $116,000 | $0 |
| Net Common Stock Issuance | $0 | $1,573,000 |
| Common Stock Issuance | $0 | $1,573,000 |
| Other | ||
| Repayment Of Debt | $-86,700 | $-50,000 |
| Issuance Of Debt | $1,069,972 | $110,000 |
| Interest Paid Supplemental Data | $124,886 | $10,000 |
| Income Tax Paid Supplemental Data | $0 | $0 |
| End Cash Position | $58,668 | $600,263 |
| Beginning Cash Position | $670,263 | $160,607 |
| Changes In Cash | $-611,595 | $439,656 |
| Proceeds From Stock Option Exercised | $152,390 | $525,000 |
| Net Issuance Payments Of Debt | $983,272 | $60,000 |
| Net Short Term Debt Issuance | $983,272 | $60,000 |
| Short Term Debt Payments | $-86,700 | $-50,000 |
| Short Term Debt Issuance | $1,069,972 | $110,000 |
| Net Intangibles Purchase And Sale | $-76,905 | $-14,500 |
| Purchase Of Intangibles | $-76,905 | $-14,500 |
| Net PPE Purchase And Sale | $0 | $-6,834 |
| Purchase Of PPE | $0 | $-6,834 |
| Change In Working Capital | $2,741,282 | $549,026 |
| Change In Payables And Accrued Expense | $2,667,640 | $592,320 |
| Change In Prepaid Assets | $48,642 | $-18,294 |
| Change In Receivables | $25,000 | $-25,000 |
| Other Non Cash Items | $1,037,478 | $124,674 |
| Stock Based Compensation | $278,804 | $2,889,567 |
| Asset Impairment Charge | $3,800 | $16,958 |
| Depreciation Amortization Depletion | $7,956 | $6,744 |
| Depreciation And Amortization | $7,956 | $6,744 |
| Net Income From Continuing Operations | $-5,604,893 | $-5,340,354 |
Fetched: 2026-02-02